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In Brief
Ultrathin, flexible optofluidic neural
probes enable wireless delivery of agents
and optical manipulation in deep brain
tissue of freely behaving animals.
Combinatorial optogenetic,
pharmacological, and viral approaches
yield a powerful tool for in vivo dissection
of neural circuitry.
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In vivo pharmacology and optogenetics hold tremen-
dous promise for dissection of neural circuits,
cellular signaling, and manipulating neurophysiolog-
ical systems in awake, behaving animals. Existing
neural interface technologies, such as metal can-
nulas connected to external drug supplies for phar-
macological infusions and tethered fiber optics for
optogenetics, are not ideal forminimally invasive, un-
tethered studies on freely behaving animals. Here,
we introduce wireless optofluidic neural probes that
combine ultrathin, soft microfluidic drug delivery
with cellular-scale inorganic light-emitting diode
(m-ILED) arrays. These probes are orders of magni-
tude smaller than cannulas and allow wireless, pro-
grammed spatiotemporal control of fluid delivery
and photostimulation. We demonstrate these de-
vices in freely moving animals to modify gene
expression, deliver peptide ligands, and provide
concurrent photostimulation with antagonist drug
delivery to manipulate mesoaccumbens reward-
related behavior. The minimally invasive operation
of these probes forecasts utility in other organ
systems and species, with potential for broad662 Cell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc.application in biomedical science, engineering, and
medicine.INTRODUCTION
Fundamental insights into the function of the central and periph-
eral nervous system often follow from advances in tools and
methodologies for neuroscience research. Technologies for
deep brain optical manipulation of neural activity allow for
many types of basic research into neural circuits (Tye and Dei-
sseroth, 2012), intracellular signaling (Siuda et al., 2015; Zhang
and Cui, 2015), gene expression (Konermann et al., 2013; Pol-
stein and Gersbach, 2015), and other biological processes.
Additional levels of control follow from combined use of such
approaches with pharmacological delivery (Jennings et al.,
2013; Stamatakis et al., 2013; Walsh et al., 2014). Furthermore,
the potential of these combinatorial approaches for clinical
impact was recently demonstrated using combined optical and
pharmacological intervention to inform and modify traditional,
electrical deep brain stimulation to be more effective for off-label
psychiatric disorders (Creed et al., 2015). A key technological
challenge has been the development of miniaturized, self-con-
tained systems that are capable of providing such functionality
with wireless control in freely moving, awake animal models.
Conventional methods rely on metal tubes (cannulas) and fiber
optic cables to deliver drugs and light, respectively. Typically,
each modality requires connection to separately located light
and fluid sources that physically tethers the animals and restricts
their natural movement. Recent advances have combined can-
nulas and fiber optics into small, multifunctional fibers that
have capabilities in fluid delivery and photostimulation but that
retain similar requirements for multiple, external connections
(Canales et al., 2015). All of these technologies use rigid mate-
rials as neural interfaces leading to adverse consequences for
chronic use. The tissue benefit of mechanical compliance was
recently demonstrated comparing standard systems against
systems that combine soft electrodes and microfluidic struc-
tures in epidural implants (Minev et al., 2015) (see Table S1 for
feature comparison).
The approach we report here describes complete platforms
that include power supplies, control electronics, wireless inter-
faces, active fluidic handling systems, and efficient light sources
into compact, head-mounted devices that interface with thin,
mechanically compliant multifunctional neural probes. The result
is a set of unique capabilities in programmed delivery of multiple
types of pharmacological agents and monochromatic light to
discretely targeted regions of the deep brain. These systems,
which we refer to as wireless optofluidic neural probes, create
important opportunities in neuroscience research that combine
in vivo pharmacology with wireless optogenetics. Examples in
awake, freely moving animals demonstrate the sophisticated
levels of spatiotemporal control over neural circuit functions
that are possible without physically contacting the animal. Spe-
cifically, optical manipulation of projections from the ventral
tegmental area dopaminergic system into the nucleus accum-
bens can elicit place preference behaviors that can be blocked,
in a temporally precise programmable manner, by site-specific
infusion of a dopamine receptor antagonist. These and related
studies represent the sort of versatile, complex experimental op-
tions provided by these optofluidic neural probes.
RESULTS
Ultrathin, Soft Neural Probes HaveWireless Capabilities
for Programmed Drug Delivery and Photostimulation
Figures 1A–1C show schematic illustrations and photographs of
amultichannel, soft microfluidic system inwhich two thin, narrow
pieces of the elastomer polydimethylsiloxane (PDMS) bond
together to form a set of four channels each with 10 3 10 mm2
cross-sectional areas in a platform that has a total thickness of
50 mm (Figures S1A–S1C). These microfluidic probes (Figures
1B and 1C) are transparent (>95% throughout across wave-
lengths from 400 nm to 700 nm) and mechanically soft (modulus
1 MPa; bending stiffness 13–18 N/m), thereby enabling both
optical access and minimally invasive use in soft neural tissue
(Canales et al., 2015; Capadona et al., 2012; Jeong et al.,
2015; Kim et al., 2013b; Kozai et al., 2012; Minev et al., 2015;
Subbaroyan et al., 2005; Wu et al., 2013). The former character-
istic facilitates integration of microscale inorganic light-emitting
diodes (m-ILEDs) on a filament of polyethylene terephthalate
(PET) with a thickness of 6 mm (Figure 1D). These m-ILEDs (lateral
dimensions of 1003 100 mm2 and 6.54 mm thick; Figure 1E) (Kim
et al., 2013b) provide spatially and temporally precise delivery of
light adjacent to the outlets of the microfluidic channels. Activeinfusion of multiple drugs through these four individual channels
(Figure 1F) can be controlled independently from the m-ILEDs.
This system allows for tandem pharmacological and optogenetic
manipulation of neural circuitry, with potential for application in
optopharmacology where the use of light to activate compounds
requires high spatiotemporal control of both drug and light deliv-
ery (Kramer et al., 2013) (Figure 1G and Movie S1).
Figures 1G, 1H, and 1I provide comparisons of this type of
compliant optofluidic probe to a standard metal cannula (see
also Figures S1D–S1H). The latter is hard, rigid, and displaces
large amounts of brain tissue (diameter 500 mm), whereas
the former is soft, flexible, and minimally invasive (total
thickness 80 mm). The low bending stiffness (13–18 N/m,
compared to >5 MN/m for the 26 gauge cannula) of the optoflui-
dic probes (Figure S2A) facilitates adaptation to the micromo-
tions associated with movement, respiration, and blood flow
(Gilletti and Muthuswamy, 2006). This property minimizes me-
chanically induced damage or irritation of the brain tissue in
chronic applications (Lee et al., 2005). X-ray computed tomo-
graphic images of mice implanted with these two types of fluidic
delivery systems highlight the notable differences in scale and
impact on the tissue (Figures 1H and 1I). Together, these opto-
fluidic probes offer minimally invasive capabilities for combined
fluid and photon delivery.
Thermo-Mechanical-Fluidic Characteristics of the
Optofluidic Devices
Figure 2A presents a schematic diagram of the overall system
with emphasis on the fluid-controlling hardware. The schemes
for fluid handling and pumping represent extensions of recently
reported drug delivery systems that use rigid, single-channel
and single-reservoir microfluidics and wired control interfaces
(Spieth et al., 2012). Each of the four channels connects to a
separate reservoir whose base consists of an active layer
(2:1 mixture of PDMS and expandable microspheres, Expancel
031 DU 40, AkzoNobel) that initiates pumping through expan-
sion induced by Joule heating in an underlying element
(serpentine traces of gold with thickness of 185 nm). The active
layer increases in volume from thermally induced, irreversible
expansion of hollow polymer microspheres that encapsulate
hydrocarbon gas (Figure 2B). The supporting substrate (FR4)
has low thermal conductivity (0.4 W/m$K), thereby minimizing
the electrical power needed to reach the temperatures
required for this type of thermal actuation. The four reservoirs
exist as molded features in a cyclic olefin polymer (COP), cho-
sen for its low water vapor permeability (0.023 g$mm/m2$day).
Thin copper membranes (3 mm) seal the outlets of the reser-
voirs to prevent evaporation. This design allows delivery of
multiple fluids without the repeated insertion of a delivery
probe.
Activating a Joule heating element launches expansion of the
corresponding active layer (Figure S2B). The resulting pressure
in the reservoir ruptures the thin copper membrane and pumps
the drug, with nearly 100% efficiency in volume delivery (0.5 ml
in this case; Figure 2C), through the respectivemicrofluidic chan-
nel. Quantitative measurements and numerical modeling (see
Supplemental Experimental Procedures and Table S2 for details)
based on finite element analyses (FEA) capture the thermal andCell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc. 663
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Figure 1. Ultrathin, Soft Neural Probes with Wireless Capabilities in Programmed Drug Delivery and Photostimulation
(A) Schematic diagram of the assembly of a soft microfluidic probe. Bonding thin, molded (bottom), and unmolded (top) layers of PDMS together yields a system
that includes four separately addressable microfluidic channels, each with cross-sections of 103 10 mm2 and a total thickness of 50 mm and width of 500 mm, as
illustrated in the inset at the bottom right.
(B) Optical micrograph of a microfluidic probe formed in this way. (Inset) Magnified view of the channels. Scale bar, 100 mm.
(C) Picture that illustrates the soft, compliant mechanics of the device.
(D) Schematic diagram of the integration of a soft microfluidic probe with a flexible array of m-ILEDs (each with lateral dimensions of 100 3 100 mm2 and
thicknesses of 6.54 mm) and metal interconnect traces on a film of PET (thickness of 6 mm).
(E) Optical micrograph of an integrated probe, which we refer to as an optofluidic system. (Inset) Colorized SEM of a representative m-ILED (contact electrodes,
yellow; spreading layer, blue). Scale bar, 100 mm.
(F) Tilted view of an optofluidic probe that shows the tip end. (Inset) SEM of the outlets of the microfluidic channels. Scale bar, 50 mm.
(legend continued on next page)
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mechanical aspects of operation. Because the modulus of the
COPmaterial (2.6 GPa) is much higher than that of the expand-
able polymer (3.0 MPa), deformations induced by thermal
actuation are almost exclusively accommodated by the latter,
as shown by both experimental and FEA results (Figures 2C,
S2C, S2D, and S2F). Quantitative studies (Figure 2C) indicate a
negligible amount (<8.5%) of infusion for heating of the active
layer to temperatures below75C, followed by a rapid increase
above 82C, finally reaching complete infusion (>99.5% of the
volume of the reservoir) at 87C. This nonlinear behavior
originates from the nonlinear thermal expansion properties (Fig-
ure 2B). FEA results for the spatiotemporal temperature distribu-
tion of isolated Joule heating elements agree with IR images, as
shown in Figure S2E, thereby validating the use of computation
in design optimization (Figure S2G). The increase in temperature
decays rapidly along both the thickness and in-plane directions
(Figures 2D and S2H) to allow efficient individual control of the
reservoirs. Computed and measured temperatures at represen-
tative locations for times before, during, and immediately after
actuation appear in Figure 2E. The average temperature of the
fluid in the reservoir remains in a range (< 60C) compatible
with many pharmacologically active compounds (Callahan
et al., 2001; Joyce et al., 1984; Steger et al., 1996). Calculations
based on a simplified fluid dynamics model (see Supplemental
Experimental Procedures for details) indicate that the fluid cools
significantly as it flows down the microfluidic channels before
penetrating the targeted tissue (<0.1C higher than the tempera-
ture of the surroundings). Therefore, this transient heating of the
fluid does not appear deleterious to either the fluid or the tissue.
Figure 2F (left) provides a schematic illustration of control
hardware and associated electronics, along with the key compo-
nents that directly support the array of m-ILEDs and the soft
microfluidic probe. A battery-powered infrared (IR) wireless
module enables independent control of fluid delivery and optical
activation. The system uses serial communication between a
separate IR transmitter (950 nm wavelength) and the receiver
to provide programmable activation of individual heaters in the
array (heater 1, 2, 3, or 4) and the m-ILEDs (in this case 5, 10,
20, or 40 Hz with 10 ms pulse width; Figure S3A). A thin, flexible
printed circuit board (PCB) serves as a substrate for a microcon-
troller (556-ATTINY84-20MU, Atmel), transistors, and an IR
detector with wide sensing angle (120; IR Sensor IC 38 kHz,
Vishay Semiconductors). Two small, rechargeable lithium ion
batteries (GM300910H, PowerStream Technology; Figure S3B)
provide power. The entire collection of components (including
the optofluidic probe, microfluidic reservoirs and actuators,
the wireless module, and two batteries) is sufficiently lightweight
(1.8 g) to allow head mounting on adult mice and rats (Fig-
ure S3C). The wireless module and rechargeable batteries
release from the optofluidics to allow quick replacement,
thus facilitating long-term operation in various behavioral
experiments.(G) Optofluidic neural probe during simultaneous drug delivery and photostimulati
(bottom; outer and inner diameters of 500 and 260 mm, respectively). Scale ba
(H and I) X-ray computed tomographic images of the mouse models with (H) an
devices are colorized green.
See also Figure S1 and Table S1.Figure 2F (right) and Movie S1 demonstrate wireless opera-
tion of drug delivery and optical stimulation with a compact,
self-contained device in a 3D-printed enclosure. Upon wireless
triggering, the microcontroller activates a selected heater for
drug delivery. The infusion rates non-linearly increase up to
5.2 ml/min, such that most of the fluid is delivered within
13 s after initiating actuation (Figure 2G). The time dynamics
of the expansion process and the geometries of the reservoirs
and channels define these rates. Therefore, engineering the ge-
ometries of reservoirs and the dimensions of the channels can
modulate the flow rate for different applications. Demonstration
experiments using aqueous solutions of colored dyes and
phantom brain tissue (0.6% agarose gel) verify these opera-
tional characteristics, as shown in Figures 2H and 2I and Movie
S2. Figure 2J shows results for total volumes of fluid delivered
from a set of reservoirs in a representative device. The
observed wireless operational characteristics of these optoflui-
dic probes offer powerful tools for integration with living neural
tissue.
Optofluidic Devices Are Suitable for Wireless
Pharmacology and Optical Manipulation in Awake,
Behaving Animals
For application in vivo, the optofluidic drug delivery device can
be chronically packaged with the platform for wirelessly trig-
gered operation that includes infrared remote control, battery
power, fluid reservoirs, and pumps with associated control elec-
tronics, all contained in a small head stage (Figures 3A and S5
and Movies S1, S2, and S3). To extend the lifetime of operation
and reduce the impact on smaller organisms, the packaged elec-
tronics for the optofluidic device can be acutely affixed to an
awake animal for acute device operation (Figure 3B). Mice with
the fully encapsulated, chronically implanted wireless optofluidic
devices interfaced to the dorsal striatum perform the rotarod test
of sensorimotor control equally as well as cannula-implanted
controls (Figures 3C and S5H). Also, when allowed to choose
when and how to run on a wheel, optofluidic-implanted
mice run equally well as cannula-implanted controls (Figures
3D and S5I). Furthermore, chronic implantation does not alter
anxiety-like behavior in the open field test (Figure 3E), an indica-
tion that bearing the device is not inherently stressful. These re-
sults indicate that even small mammals such asmice tolerate the
chronically implanted probes equally as well as mice with con-
ventional cannulas targeting the same brain structure. It is impor-
tant to note that the cannulated mice in these experiments were
not connected to an external drug supply. Such tethering can
further restrict movement and negatively impacts performance
on these tests, whereas the optofluidic-device-implanted mice
are fully integrated with both the device and the fluid supply. In
addition to comparable behavioral responses, the mechanical
compliance and smaller overall tissue displacement of the mi-
crofluidic channels reduce lesioning and immunoreactive glialon. (Insets) Comparison of such a device (top) and a conventional metal cannula
rs, 1 mm.
optofluidic neural probe and (I) a metal cannula implanted into the brain. Both
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Figure 2. Thermo-Mechanical-Fluidic Characteristics of Wireless Optofluidic Systems
(A) Exploded view schematic diagram that illustrates an array of m-ILEDs mounted on top of a soft microfluidic system that includes four separate microfluidic
channels, each connected to a set of fluid reservoirs that include copper membranes as hermetic seals, expandable composite materials as mechanical
transducers, and microscale Joule heating elements as actuators.
(B) Characteristics of a thermally expandable composite material. (Left) Thickness variation of this material as a function of temperature. (Right) SEM images
(scale bar, 100 mm) show the expansion of microspheres upon application of heat at 110C.
(C) Dependence of the infused volume, as a percentage of the total volume of the reservoir, on temperature of the composite material. The dashed line indicates
100% infusion at 87C. (Inset top) Cross-sectional SEM image that shows complete filling of a reservoir with composite material by thermal expansion for a state
of 100% infused volume. (Inset bottom) Corresponding distribution of vertical displacements in the composite material under the deformed configuration.
(D) Calculated temperature distribution at the surface of the entire three-dimensional computational model (top) and that at the cross-section defined by the red
plane in the top (bottom).
(E) Computed (blue) and measured (red) temperature at the location of a thermal actuator immediately before, during, and after operation. The violet, green, and
yellow curves correspond to calculations at the reservoir, the microfluidic inlet and outlet, respectively.
(legend continued on next page)
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responses from deep brain implantation (Figures 3F–3J and
Table S3). Additionally, the optofluidic devices provide access
to four channels of drug, viral, or other fluid administration
compared to a single channel for the cannula in a significantly
smaller cross-sectional area (Figure 3G) of the brain. These
thin, flexible optofluidic neural probes are better tolerated by
the brain than rigid implants, consistent with previous reports
of ultrathin, flexible deep brain implants (Canales et al., 2015;
Capadona et al., 2012; Kim et al., 2013b; Kozai and Kipke,
2009; Kozai et al., 2012).
Wireless Virally Mediated Recombination and
Visualization of Fluid Delivery
As a demonstration of the optofluidic probes’ ability to deliver
multiple, independent fluids through a single implant in an awake,
behaving animal, we loaded two reservoirs with two different ad-
eno-associated viruses to allow for recombination-dependent
fluorescent visualization of successful fluid ejection. First, we
delivered a virus expressing Cre recombinase (AAV5-PGK-Cre)
into the dorsal striatum of a Cre-conditional tdTomato reporter
mouse line (Ai9) developed by theAllen Institute for Brain Science
(Figure 4A) (Madisen et al., 2010). We observed robust Cre-
dependent expression of tdTomato in a distinct radius below
the ventral tip of themicrofluidic channels, thereby indicating effi-
cient remote-controlled, virally induced in vivo recombination
(Figure 4A). When we counted the number of tdTomato+ cells
emanating from the tip of the implant, we found the majority of
the Cre-induced fluorescent reporter expression to be within
500 mmof the injection site (Figure 4B). Next, in a separate group
of animals, we delivered the same AAV5-PGK-Cre, as well as a
Cre-dependent eYFP reporter virus (AAV5-Ef1a-DIO-eYFP). In
these animals, we clearly observed co-expression of both
tdTomato and eYFP (Figures 4C–4E), indicating successful,
combinatorial viral-mediated recombination in vivo. These are
proof-of-principle experiments, but the same approach could
beused towirelessly alter gene expression atmultiple timepoints
without the need for multiple, disruptive surgeries or physical
connection to viral infusion hardware. Together, these results
further demonstrate that the optofluidic neural probes can be
used for in vivo remote-controlled, independent delivery of fluids
within an isolated region through individual and distinct channels
running along a single implant.
Untethered, Programmed Pharmacological Infusion
Alters the Behavior of Freely Moving Animals
The capability to load a single device with multiple fluids for
independent, remote-controlled delivery offers the user the(F) Complete wireless optofluidic system. (Left) Schematic illustration of the elect
in Figure 2A. (Right) Demonstration of wireless drug delivery and optical stim
(0.6% agarose gel).
(G) Flow rate in a microfluidic channel (blue) and total infused volume (red) as a f
(H) Time sequence of optical images that demonstrates delivery of liquid (aqueous
a microfluidic channel: t1 = 0 s (onset of actuation), t2 = 3.1 s, t3 = 3.8 s, and t4
(I) Images that show capabilities in separate delivery of different liquids (aqueo
microfluidic channels. The image on the right provides a magnified view.
(J) Total infusion volumes from each of four reservoirs in representative devices
See also Figures S2, S3, S4 and Movies S1 and S2.advantage of either multiplexed treatments or easily controlled
within-subject study designs. As a demonstration of the latter,
we implanted microfluidic devices unilaterally into the ventral
tegmental area (VTA) of wild-type (C57Bl6) mice. Previous re-
ports have demonstrated a remarkably stereotyped rotation
behavior to unilateral m-opioid receptor (MOPR) activation in
the VTA (Devine and Wise, 1994; Jenck et al., 1988). As a
proof-of-principle within-subject in vivo pharmacology experi-
ment, two chambers of each device were loaded with different
pharmacological agents—one with the synthetic opioid peptide
and MOPR agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin
(DAMGO, 200 pmol, Tocris) and one with artificial cerebral spinal
fluid (ACSF) as a vehicle control. In a counter-balanced design,
we then wirelessly delivered either the DAMGO or vehicle into
the VTA of freely behaving animals over a distance of 1 m
away from the animal (Figures 5A and 5B). Consistent with pre-
vious reports (Calenco-Choukroun et al., 1991; Devine and
Wise, 1994; Jenck et al., 1988; Latimer et al., 1987), when
DAMGO was infused into the VTA, the animals showed a robust
increase in overall locomotor activity (Figures 5C–5E). In partic-
ular, the unilateral administration causes stereotypical rotations
contralateral to injection site that is completely absent when
the same animals receive the wireless ACSF infusion (Figures
5B, 5C, and 5E). This experiment demonstrates the utility of
the optofluidic probes for self-contained, within-subject experi-
ments to wirelessly deliver multiple chemicals into the brain
without any physical contact with the animal for unconstrained
freely moving behavior.
Concomitant Wireless Photostimulation with Wireless
Pharmacological Antagonism Modulates a
Dopaminergic Real-Time Place Preference
We next determined the in vivo optofluidic capabilities of these
devices. Real-time place preference has become a common
tool for neuroscientists to assess the behavioral valence of pho-
tostimulated neural circuits or cell bodies in a freely moving
animal (Jennings et al., 2013; Kim et al., 2013a; Siuda et al.,
2015; Stamatakis and Stuber, 2012; Stamatakis et al., 2013;
Tan et al., 2012). In related behavioral models, phasic optoge-
netic activation of VTA dopaminergic (VTA-DA) neurons is
rewarding (Kim et al., 2012, 2013b; Tsai et al., 2009; Witten
et al., 2011). However, we previously failed to observe that wire-
less phasic activation of VTA-DA cell bodies was sufficient for a
real-time place preference (Kim et al., 2013b). Because of the
pronounced heterogeneity of VTA projections (Gunaydin et al.,
2014; Lammel et al., 2011, 2012, 2015; Stamatakis et al., 2013;
Stuber et al., 2015), we sought to selectively target VTA-DAronics, power, and wireless control system that plugs into the construct shown
ulation by operation of the optofluidic system in a brain tissue phantom
unction of time before, during, and after actuation.
solution with orange dye) into brain phantom tissue (0.6% agarose gel) through
= 15.2 s.
us solutions with red, yellow, blue, and green dyes) through four individual
(average of three devices).
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Figure 3. Optofluidic Devices Are Suitable for Wireless Pharmacology in Awake, Behaving Animals
(A and B) Images of a freely behaving (A) Sprague-Dawley rat and (B) a C57Bl6mousemounted with wireless power systems that are capable of drug delivery and
photostimulation deep into brain tissue. All animals are healthy and freely moving, shown here 1 week following surgery. Scale bars, 1 cm.
(C–E) Wild-type (C57Bl6) mice tolerate the microfluidic devices, as well as traditional cannulas, and do not exhibit any notable deficits in (C) motor coordination,
(D) spontaneous locomotor activity, or (E) anxiety-like behavior.
(F) Schematic andMouse Brain Library atlas image of histological approach for inflammation and lesion study. Dashed circle indicates approximate injection site.
Scale bar, 1 mm.
(G) Mean ± SEM cross-sectional area of lesions from cannulas and optofluidic probes (Student’s t test, **p < 0.01, n = 3/group).
(H) Representative linescan of fluorescence intensity from cannula (gray) and optofluidic probe (red) lesions.
(I and J) Representative confocal fluorescence images of 30 mm horizontal striatal slices show immunohistochemical staining for Nissl bodies (blue), astrocytes
(GFAP, red), and activated microglia (Iba1, green) and overall lesion from a cannula (I) and an optofluidic device. All histological and confocal settings were kept
consistent across groups. (J) In the rightmost panels, the shape and scale of the lesion from the cannula or optofluidic device is overlaid on the image of the other
device (dashed lines). Scale bars, 100 mm. See also Figure S5 and Movie S3.projections into the shell of the nucleus accumbens (NAcSh). To
do this, we selectively targeted channelrhodopsin-2 fused with
eYFP (AAV5-EF1a-ChR2(H134)-eYFP) to VTA-DA neurons of668 Cell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc.TH-Cremice and implanted an integrated optofluidic probe adja-
cent to the NAcSh (Figures 6A, 6B, and S6A–S6C). In this exper-
iment, we found that photostimulation of the NAcSh-projecting
A B
C
D E
Figure 4. Wireless Virally Mediated Recombination Visualizes the Spread of Fluid Delivery
(A) Schematic of viral delivery experiment depicting loading of two distinct viruses into a single microfluidic device; fluorescence image depicts bolus of Cre-
mediated recombination (imaged as expressed tdTomato, red; Nissl, blue) near the tip of the implanted microfluidic device. Right, enlarged maximum projection
of 35 confocal fluorescence images (tdTomato, red). Black scale bar, 1 mm; white scale bar, 25 mm.
(B) Quantification of the spread of AAV5-PGK-Cre viral recombination. Cells counted in serial coronal slices from point of infusion (n = 3 slices per brain from
3 brains).
(C) Viral recombination scheme for the dual viral approach taken in (D) and (E).
(D) Representative maximum projection of 35 confocal fluorescence images of 30 mm coronal striatal slices demonstrates efficient virally induced gene
expression (left-tdTomato, red; middle - eYFP, green, right-overlay) following wireless delivery of viruses. Chevron indicates example co-localization of tdTomato
and eYFP. Scale bar, 25 mm.
(E) Quantification of co-localization of tdTomato (tdT) and eYFP (n = 3 slices per brain from 3 brains).VTA-DA fibers resulted in an increase in c-fos expression, a
widely used biochemical marker of neuronal activation, in both
the accumbens and the ventral tegmental area (presumably
through antidromic activation) (Figures S6D and S6E and Table
S3). To test whether any of the observed behavioral phenotypes
were dopamine dependent, we filled one chamber of the opto-
fluidic device with the selective dopamine receptor D1 (DRD1)
antagonist SCH23390 (400 ng, Tocris) (Billard et al., 1984;
Gunaydin et al., 2014; Hyttel, 1983). We found that phasic
photostimulation (8 3 10 ms light pulses at 20 Hz every 5 s) of
VTA-NAcSh terminals was able to drive a robust real-time place
preference (Figures 6C and 6D). Importantly, in a counter-balanced design, this place preference was completely blocked
by wireless pharmacological delivery of SCH23390 prior to
photostimulation in the real-time place preference task, indi-
cating that optogenetically induced dopamine release into the
NAcSh elicits the real-time place preference via DRD1 activation.
There was no effect of either the photostimulation or the drug
treatment on TH-Cre control animals that did not express
ChR2(H134)-eYFP (Figures 6E and 6F), and no treatment group
displayed a significant effect on locomotor activity (Figure 6G).
These findings demonstrate that completely self-contained,
remote-controlled optofluidic neural probes can be easily incor-
porated into optogenetic studies to introduce pharmacologicalCell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc. 669
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Figure 5. Untethered Delivery of Mu-Opioids into the Ventral Tegmental Area Causes Stereotypical, Repeated Rotation Behavior
(A) Schematic of the opioid peptide delivery experiment depicting loading of an agonist (200 pmol DAMGO, Tocris) and its vehicle into single microfluidic device.
(B) Cartoon of wireless scheme for the DAMGO-induced rotation experiment.
(C) Representative traces of movement from the same animal over the course of 2 min and 1 hr clearly show an increase in overall movement and rotations.
(D and E) Within-subject, counter-balanced experiments demonstrate robust wireless, DAMGO-induced changes in ambulatory behavior. Intra-VTA DAMGO
causes a significant increase in (D) overall locomotion and (E) contraversive 360 rotations (n = 7, paired Student’s t test, **p < 0.01).agents into the immediate region of targeted photostimulation in
a programmed fashion that is time locked and dependent on the
behavior.
DISCUSSION
The wireless optofluidic neural probes presented here represent
a compelling technology for programmable drug delivery and
optical manipulation of deep brain tissue in freely moving ani-
mals. The resulting device platform has multifunctional capabil-
ities in a single, soft implant that provides powerful options for
in vivo pharmacology and wireless optogenetics, many of which
would be impossible to reproduce with conventional metal can-
nulas and/or optical fibers.
A key advantage of these systems is the spatial specificity
inherent in the multimodal brain/device interface. Previous dem-
onstrations of wireless drug delivery have focused on defuse
infusion of drug into the subcutaneous space of rats and,
recently, humans (Farra et al., 2012; Hoare et al., 2009, 2011;
Timko et al., 2014). Although these devices are capable of on-
demand fluid delivery, they are unable to couple to the types of
microfluidic channels necessary for discrete, targeted fluid deliv-
ery into deep brain tissue. The wireless optofluidic probes re-
ported here overcome this challenge with a single device that
causes a single, static lesion to brain tissue, where fluids and
photons arrive at precisely the same micro-region of the brain.
This co-localization targets the same cells with both drugs and
photostimulation. One interesting possibility is in delivery of viral670 Cell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc.vectors for expression of exogenous receptors (light-sensitive
ion channels, receptors, pumps, etc. or DREADD receptors),
ligands for these or endogenous receptors, and photostimula-
tion all to the same brain region and cell population. The
compact, self-contained construction eliminates the repeated
micro-lesions associated with internal cannulas and the angled
lesions associated with exterior fiber optics, dramatically
reducing overall trauma to the brain (Figures 3F and 3G). This
minimally invasive operation facilitates a within-subject experi-
mental design, thereby reducing the number of animals one
needs to account for the behavioral variability that arises from
any significant disruption of brain tissue. The soft neural inter-
faces enabled by these ultrathin, compliant probes also create
new opportunities for chronic neuroscience research and pre-
clinical investigation, as demonstrated not only here but also in
recent studies of other soft device technologies for use in the
epidural space (Minev et al., 2015). Importantly, the materials
and designs presented here represent significant advances
over these and other neural interfaces, all of which rely on teth-
ered operation and lack capabilities in both wireless operation
and photostimulation (Table S1) (Canales et al., 2015; Minev
et al., 2015; Spieth et al., 2012). An important perspective is
that the platforms reported here can easily be adapted for a
wide range of other types of passive or active electronics tech-
nologies, including electrical microstimulation.
For any configuration, the value of the technology to the com-
munity depends on the extent to which it can be widely adopted.
In this context, a relevant consideration is that the hardware for
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Figure 6. Wireless DRD1 Antagonism in the NAcSh Blocks Photostimulation-Induced Real-Time Preference of Freely Moving Animals
(A) Schematic of the optofluidic experiment. AAV5-EF1a-DIO-ChR2-eYFP was injected into the VTA, and 6 weeks later, an optofluidic probe loaded with
SCH23390 (400 ng, Tocris) was implanted in the NAc of TH-Cre animals.
(B) Representative confocal fluorescence images depicting cell-type-specific expression of ChR2-eYFP in (right) dopaminergic, TH-containing neurons of the
VTA (TH, red; ChR2-eYFP, green) and (left) their projections in the NAc (Nissl, blue; ChR2-eYFP, green). Triangular arrow indicates the ventral tip of the
microfluidic channels, and the chevron indicates the ventral tip of the optofluidic device. All scale bars for the figure are 100 mm.
(C–G) Phasic photostimulation (8 pulses at 20 Hz, 10ms pulse width upon entry and every 5 s the animal remains in the chamber) of NAc-projecting terminals from
the VTA of TH-Cre animals drives a real-time place preference.
(C) Representative traces of movement during the real-time place testing experiment of one TH-CreVTA:ChR2 animal show a SCH23390-sensitive preference for
the photostimulation-paired chamber.
(D) All TH-CreVTA:ChR2 animals show a real-time place preference that is significantly reduced following wireless intra-NAc delivery of SCH23390 (n = 9, paired
Student’s t test, ***p < 0.001).
(E) In Cre control animals, neither the photostimulation nor the SCH23390 treatment affects real-time preference behavior (n = 8, paired Student’s t test,
p = 0.6234).
(F) Grouped analysis confirms that the SCH23390-sensitive place preference is selective for the TH-Cre+ animals (n = 8–9/group, one-way ANOVA, Bonferroni
Post hoc, **p < 0.01, ****p < 0.0001).
(G) There is no significant difference between any groups for overall locomotor activity (n = 8–9/group, one-way ANOVA).
See also Figure S6.control and power management consists of readily available
electronics hobbyist components (Figures S3 and S4). Aside
from a simple IR remote control, the animal carries a small IR
receiver systemwith little observable impact on its behavior (Fig-
ure 3 andMovie S3). In fact, after the initial surgery to implant and
secure the device to the skull, the experimental subject never
needs to come in contact with a human again. Complete opera-
tion of these optofluidic neural probes, including delivery of up to
four distinct pharmacological agents, viruses, or other fluids, as
well as photostimulation, can all be achieved wirelessly in any
domain through which the IR signal can pass.
Areas for further improvement include dynamic control of
fluid flow. Although the reported devices provide for multiple
delivery events, each operates with identical rates of infusion
(Figure 2G). While the infusion rate of the probes presented
here could be faster than ideal for some desired applications,
wedid not directly observe any deleterious effects to either tissueor behavior associated with vehicle infusions. Nevertheless, en-
gineered variations in the dimensions of the reservoirs and chan-
nels represent one means to define slower infusion rates and
different flow conditions. Furthermore, care should be taken to
ensure that the chosen fluids are compatible with delivery in
these systems. Figure 2E demonstrates some transient heat
transfer to the fluid prior to delivery. We purposefully chose to
use potentially temperature-sensitive compounds (i.e., neuro-
peptides and viral vectors) and, in these cases, did not observe
any limitations associated with delivery from these probes. How-
ever, it is important to empirically determine the thermal stability
of each compound to be used in these systems. Another limita-
tion is in refilling devices. With the current layouts, reuse of the
microfluidics reservoirs and channels can be challenging. To
overcome these restrictions, implementing replaceable fluid-
containing cartridges (analogous to ink jet printer cartridges)
might represent an attractive future design feature.Cell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc. 671
Even in existing embodiments, the device capabilities allow
previously intractable experiments such as altering gene expres-
sion in freely behaving animals while living in their native home
cage environments (Figures 4 and S5). The optofluidic neural
probes can also provide photostimulation and delivery of phar-
macological agents in a closed-loop manner based on the ani-
mals’ behavior (Figures 6 and S6). Integration with real-time
video acquisition of socially interacting animals (de Chaumont
et al., 2012; Kunwar et al., 2015) would allow fully automated,
programmed fluid delivery that could be tuned entirely to the so-
cial interactions of the animal. Beyond the possibilities in optoge-
netics, all of which require genetic modification, an interesting
application could be in optopharmacology. The use of photo-
sensitive compounds that act as photo-switches or ligands
that bind to channels or receptors upon photo-conversion
(Kramer et al., 2013) could exploit the high spatiotemporal con-
trol of both fluid and light delivery afforded by these optofluidic
probes. Optopharmacological agents have been enthusiastically
received in neuroscience for in vitro applications (Banghart and
Sabatini, 2012; Callaway and Katz, 1993; Carter and Sabatini,
2004; Matsuzaki et al., 2001), but their use in vivo has been
limited. Although compelling findings exist addressing the
external visual nervous system and the surface of the cortex
(Mourot et al., 2012; Noguchi et al., 2011; Polosukhina et al.,
2012; Tochitsky et al., 2014), optopharmacological application
in the deep brain remains a significant challenge. Optofluidic
devices that provide access to the UV spectrum with advanced
m-ILEDs could target these highly selective photosensitive tools
to spatially isolated regions of the central nervous system in non-
genetically altered mammals.
Beyond basic research, the operation and architecture of the
probes reported here will allow for a smooth translation to non-
human primate models, as well as applications in clinical medi-
cine. Therapeutic solutions for a diverse set of pathologies
(e.g., local neurooncotherapy, pharmacologically refined deep
brain stimulation, delivery of agents to mitigate traumatic brain
injury, etc.) will benefit from the untethered and fully contained,
programmable operation of devices similar in design to these
optofluidic neural probes. Such centrally targeted drug delivery
holds the promise of more tissue- and cell-type-selective thera-
pies that avoid perturbing off-target organ systems. With these
exciting future directions in mind, the results of our studies
establish strategies for minimally invasive, ultrathin wireless
optofluidic neural probes that can serve as a starting point for
new generations of fluid neural interfaces.EXPERIMENTAL PROCEDURES
Fabrication of Ultrathin, Flexible Optofluidic Probes
Fabrication of flexible microfluidic probes started with creating microfluidic
channel patterns in a 25 mm PDMS layer (Sylgard 184, Dow Corning) using a
molding process. For the mold, photo-curable epoxy (SU-8 10, Microchem)
was spin coated (3,000 rpm for 10 mm) on a silicon wafer and UV exposed
(120 mJ/cm2) through a mask pattern. Removing the unexposed region by
developing, followed by thermal annealing (65C, 2 min – 75C, 2 min –
85C, 2 min – 95C, 5 min – 65C, 2 min), completed the fluidic channel
mold. To facilitate release of patterned PDMS from the mold, it was chemically
treated with evaporated anti-stiction agent (chlorotrimethylsilane, Sigma-
Aldrich) for 20 min. PDMSwas cast on the mold and pressed with a glass slide672 Cell 162, 662–674, July 30, 2015 ª2015 Elsevier Inc.(53 3.5 cm2) that was treated with Pt inhibitor solution (5% AEAPS (3-(2-Ami-
noethylamino) Propylmethyldimethoxysilane, Sigma-Aldrich) and 95% meth-
anol) for 45 min; this inhibitor treatment facilitated release of the PDMS layer
from the glass slide by deactivating Pt at the glass-PDMS interface. The glass
slide and the mold were clamped, the PDMS between them was cured for
50min at 70C, and the glass slide with the patterned thin PDMS layer was de-
tached from the Si mold.
A flat, thin PDMS layer (20 mm) was also prepared by spin-casting PDMS
(2,000 rpm for 60 s) on a polycarbonate (PC) membrane and cured at 70C
for 1 hr. Both this flat PDMS layer on the PC membrane and the patterned
PDMS layer on the glass slidewere oxygen plasma-treated to activate their sur-
faces and bonded together to form microfluidic probes. After removing the PC
membrane, the probes were released from the glass slide without damage due
to the Pt inhibitor treatment of the glass surface. See the Supplemental Exper-
imental Procedures for fabrication details of the m-ILED array (Kim et al., 2013b;
McCall et al., 2013). The m-ILED array was integrated onto the microfluidic
probewithdouble-sided adhesive (25mm;ARclear 8154, AdhesivesResearch).
Fabrication of Optofluidic Drug Delivery Devices with Thermal
Actuators
Heater patterns were photolithographically defined on Cr/Au (5 nm/185 nm)
deposited FR-4 substrates (G10 glass epoxy sheet, ePlastics). The expand-
able layer (250 mm) was prepared on top of heaters on the FR-4 substrate by
spin coating thermally expandable polymer (2:1 mixture of PDMS [elastomer:
curing agent = 10:1] and expandable microspheres [Expancel 031 DU 40,
AkzoNobel]) and cured at 70C for 12 hr. Hemispherical reservoirs patterned
in COP were aligned on the heaters and bonded using the double-sided adhe-
sive. Parylene C (6 mm) was deposited on the inner walls of the reservoirs to
further improve vapor impermeability and chemical resistance.
For fluid loading, the reservoirs were first treatedwith oxygen plasma (March
RIE) for 30 s tomake the inner surface hydrophilic. A syringewith a blunt needle
was used to fill the reservoirs. To prevent fluid evaporation, the outlets of the
reservoirs were hermetically sealed with Cu membranes (3 mm) after loading.
Then, the inlets of an optofluidic probe were aligned and bonded with the out-
lets of the reservoirs.
Experimental Subjects
Adult (25–35 g) male C57BL/6J and TH::IRES-Cre backcrossed to C57BL/6J
mice were group housed, given access to food pellets and water ad libitum,
and maintained on a 12 hr:12 hr light:dark cycle (lights on at 7:00 AM). All
mice were held in a facility in the lab 1 week prior to surgery, post-surgery
and throughout the duration of the behavioral assays to minimize stress
from transportation and disruption from foot traffic. Adult (275–325 g) male
Lewis rats (LEW/CRL) were purchased from Charles River and housed in a
climate-controlled facility with a 12:12 hr light-dark cycle under standard con-
ditions. All procedures were approved by the Animal Care and Use Committee
of Washington University and conformed to US NIH guidelines.
Implantation of Optofluidic Neural Probes
Soft, mechanically compliant optofluidic probes were implanted into the brain
as previously described using thin (50 mm) stainless steel microneedles as
insertion shuttles (Kim et al., 2013b; McCall et al., 2013). Water-soluble, puri-
fied silk (7 wt%) was used to bond an optofluidic probe to the microneedle,
facilitating release of the microneedle after implantation. Figures S5A–S5E
shows the sequential process of the surgery, and more detailed information
can be found in the Supplemental Information.
Data Analysis/Statistics
Data are expressed as means ± SEM. Data were normally distributed, and dif-
ferences between groups were determined using independent t tests or one-
way ANOVA followed by post hoc Bonferroni comparisons if the main effect
was significant at p < 0.05. Paired t tests were used in within subject design
experiments. Statistical analyseswere conducted using Prism 5.0 (GraphPad).
Device Availability
To inquire about wireless optofluidic device availability, please contact either
of the corresponding authors via email.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, three tables, and three movies and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2015.06.058.
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